The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Nonrespiratory AE of interest
Publications
Osman GA, Marra A, Iacono D, Giannelli V, Ricciardi S, Remotti D, Vecchione A, Ricci A, Palange P, Migliorino MR
Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab: a case report.
Anti-cancer drugs 2019 Apr 03;; — 2019 Apr 03
Acute neurological adverse events during immune checkpoint inhibition therapy in patients with melanoma brain metastases.
Melanoma research 2019 Mar 22;; — 2019 Mar 22
Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy.
Cardiology in review 2019 Mar/Apr;27;97-107 — 2019 Mar/Apr — 97-107
Identifying and managing the adverse effects of immune checkpoint blockade.
Journal of thoracic disease 2018 Feb;10;S480-S489 — 2018 Feb — S480-S489